Mainstay Medical International

Equities

MSTY

IE00BJYS1G50

Advanced Medical Equipment & Technology

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-10.55%	-42.65%

Mar. 12	Mainstay Medical Holdings plc Announces Publication of Clinical Results Comparing Older Patients and Younger Patients	CI
Feb. 26	Mainstay Medical Holdings plc announced that it has received ?115 million in funding from a group of investors	CI

Mainstay Medical International plc Reports Earnings Results for the Half Year Ended June 30, 2019

September 20, 2019 at 02:00 am EDT

Mainstay Medical International plc announced earnings results for the half year ended June 30, 2019. For the half year, the company announced sales was USD 552,000 compared to USD 358,000 a year ago. Operating loss was USD 9.323 million compared to USD 15.661 million a year ago. Net loss was USD 11.146 million compared to USD 16.523 million a year ago. Basic loss per share was USD 0.0127 compared to USD 0.0201 a year ago.

Latest news about Mainstay Medical International

Mainstay Medical Holdings plc Announces Publication of Clinical Results Comparing Older Patients and Younger Patients	Mar. 12	CI
Mainstay Medical Holdings plc announced that it has received ?115 million in funding from a group of investors	Feb. 25	CI
Mainstay Medical Holdings plc announced that it expects to receive funding	Feb. 22	CI
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on Reactiv8® Restorative Neurostimulation Systemtm	Feb. 12	CI
Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States	23-08-29	CI
Mainstay Medical Holdings plc Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-Up Registry of Reactiv8 in the United Kingdom	23-07-20	CI
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Mainstay Medical Holdings plc Announces the Publication of Effect of Restorative Neurostimulation on Major Drivers of Chronic Low Back Pain Economic Impact	23-03-02	CI
Mainstay Medical Announces Publication of Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study in Chronic Low Back Pain Patients	22-11-22	CI
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
Mainstay Medical Holdings plc Announces Publication of Two-Year Patient Outcomes Data from Reactiv8-B Clinical Trial Demonstrating Long-Term Efficacy of Reactiv8 Restorative Neurostimulation	22-01-06	CI
Mainstay Medical Holdings plc Announces Appointment of Jeffrey Dunn and Eric Major to Its Board of Directors	21-12-14	CI
Mainstay Medical Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2020	21-07-09	CI
Mainstay Medical Announces Limited Announces Commercial Launch of ReActiv8® in US	21-06-29	CI
Oxford Finance LLC Announces Closing of $50 Million Senior Secured Term Loan with Mainstay Medical Holdings plc	21-04-20	CI
Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia	21-03-08	CI
Mainstay Medical Holdings plc announced that it has received $108 million in funding from Ally Bridge Group, KCK Group, Sofinnova Partners SAS, Fountain Healthcare Partners, and another investor	21-02-15	CI
Mainstay Medical Holdings plc announced a financing transaction	21-02-08	CI
Mainstay Medical Holdings plc Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain	20-06-22	CI
Mainstay Medical International plc Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-25	CI
Mainstay Medical Announces Completion of Day 100 Meeting with FDA Regarding Pre-Market Approval Application for ReActiv8	19-12-11	CI
Mainstay Medical Announces Regulatory Approval from Australian Therapeutic Goods Administration for ReActiv8	19-12-06	CI
Mainstay Medical Announces Acceptance For Filing by US FDA Of Pre-Market Approval Application for ReActiv8	19-10-01	CI
Transcript : Mainstay Medical International plc, H1 2019 Earnings Call, Sep 20, 2019	19-09-20
Mainstay Medical International plc Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-20	CI

Chart Mainstay Medical International

Duration

Period

More charts

Company Profile

Mainstay Medical International Ltd is an Ireland-based company. The Company is engaged in electromedical materials support services.

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
MAINSTAY MEDICAL INTERNATIONAL	-42.65%	29.84M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
SIEMENS HEALTHINEERS AG	+0.65%	63.06B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B

Other Advanced Medical Equipment & Technology